Frontage expand into Canada and the West Coast of North America through the acquisition of BRI
Frontage Holdings Corporation (PA, USA), a CRO with operations in the USA and China, has announced the acquisition of BRI Biopharmaceutical Research, Inc. (BC, CA) through the purchase of all outstanding BRI shares owned by J&J Corporate Services Inc. (NJ, USA). The acquisition sees Frontage expanding their geographic foothold into Canada and the West Coast of North America.
As a CRO, Frontage provides integrated research, analytical and development services to pharmaceutical companies for the entire drug discovery and development process to facilitate the success of drug development programs. With operations in the USA and China, Frontage serves two of the largest international markets for CRO services.
BRI – a CRO established in Vancouver (Canada) – offers a range of bioanalytical services, including assays for the measurement of drug candidates, metabolites and biomarkers as well as in vitro drug metabolism/ADME and in vivo DMPK/ADME studies.
The acquisition is intended to improve client access to bioanalytical services, Abdul Mutlib (EVP Frontage DMPK services) explained: “Expanding our geographic foothold into Canada and the west coast of North America will allow us to offer our clients proximal access to our DMPK and Bioanalytical Services. It will effectively increase the client base that we currently serve in this specific field, with the potential to increase our revenue generated through these highly specialized services.”
Mutlib continued: “In addition, the acquisition would extend our current contract research services into human tumor xenograft mouse efficacy models, obesity/diabetes rodent metabolic disease models, and the growing research market in human gut microbiome metabolism and biomarker assays. These services will further complement our current scientific expertise, capabilities and service portfolio to meet the needs of its broad client base.”
Song Li (Founder and Honorary Chairman of Frontage, CEO of Frontage Labs) commented: “We believe that outsourcing by the pharmaceutical industry is expected to continue to increase in North America and China. Upon completion of the acquisition, we will expand our capacity with additional scientists, equipment, and facilities to be used in the provision of existing and novel services to our customers.”
Source: https://www.frontagelab.com/about/news-item/acquisitionofbri/
